

4th International Conference on

Bioprocess and Bio Therapeutics

October 20-21, 2016 Houston, USA



Zhinan Xia

Moderna Biotherapeutics, USA

Rapid discovery of therapeutic antibody with improved drug ability and develop ability

Rapidly discover and optimize therapeutic mAb is the key factor to success in a very competitive fast changing global pharmaceutical market place. We have developed a very rapid approach that allows you to discover novel therapeutic mAb lead molecule in a few months. Here is what you need: a good humanized transgenic mice, phage/yeast display and NGS capability. This talk will demonstrate how we obtain a mAb drug development candidate in less than 4 months from mice immunization, phage display/NGS to pm affinity lead molecule identification

Biography

Dr. Zhinan Xia is a recognized leader in antibody technologies and therapeutics. He earned his Ph.D. degree in protein engineering from the College of Pharmacy at the University of Kentucky. He also completed an M.S. degree in drug design from the China Pharmaceutical University, Nanjing, China, and a B.S. degree in medicinal chemistry from Nanjing College of Pharmacy, Nanjing, China.

Zhinan.Xia@modernatx.com

Notes: